Abstract
Hypoparathyroidism is a disorder characterized by hypocalcemia and low or absent parathyroid hormone (PTH). While standard treatment of hypoparathyroidism consists of oral calcium and vitamin D supplementation, maintaining serum calcium levels can be a challenge, and concerns exist regarding hypercalciuria and ectopic calcifications that can be associated with such treatment. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. This mini-review focuses on the use of PTH in the treatment of hypoparathyroidism. There are two available formulations of PTH: teriparatide [human PTH(1-34)] and the full-length molecule, PTH(1-84). Both PTH(1-34) and PTH(1-84) lower supplemental vitamin D requirements and increase markers of bone turnover. Densitometric and histomorphometric studies in some subjects treated with PTH(1-84) demonstrate improvement in abnormal bone-remodeling dynamics and return of bone metabolism toward normal euparathyroid levels. Further detailed examination of skeletal features following therapy with the different treatment regimens and data regarding the effect of PTH on quality of life measures are under active investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M.R. Rubin, J.P. Bilezikian, Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq. Bras. Endocrinol. Metab. 54, 220–226 (2010)
S.H. Pearce, C. Williamson, O. Kifor et al., A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115–1122 (1996)
T. Sunthornthepvarakul, S. Churesigaew, S. Ngowngarmratana, A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J. Clin. Endocrinol. Metab. 84, 3792–3796 (1999)
M.R. Rubin, D.W. Dempster, H. Zhou et al., Dynamic and structural properties of the skeleton in hypoparathyroidism. J. Bone Miner. Res. 23, 2018–2024 (2008)
S. Abugassa, J. Nordenstrom, S. Eriksson, G. Sjoden, Bone mineral density in patients with chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 76, 1617–1621 (1993)
J.S. Touliatos, J.I. Sebes, A. Hinton et al., Hypoparathyroidism counteracts risk factors for osteoporosis. Am. J. Med. Sci. 310, 56–60 (1995)
M.R. Rubin, D.W. Dempster, T. Kohler et al., Three dimensional cancellous bone structure in hypoparathyroidism. Bone 46, 190–195 (2010)
M.R. Rubin, D.W. Dempster, J. Sliney Jr. et al., PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J. Bone Miner. Res. 26, 2727–2736 (2011)
T. Sikjaer, L. Rejnmark, L. Rolighed et al., The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J. Bone Miner. Res. 26, 2358–2370 (2011)
D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008)
J.P. Bilezikian, A. Khan, J.T. Potts Jr. et al., Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26, 2317–2337 (2011)
W. Arlt, C. Fremerey, F. Callies et al., Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146, 215–222 (2002)
G. Mazziotti, J. Bilezikian, E. Canalis et al., New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)
K.K. Winer, J.A. Yanovski, G.B. Cutler Jr., Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276, 631–636 (1996)
K.K. Winer, J.A. Yanovski, B. Sarani, G.B. Cutler Jr., A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J. Clin. Endocrinol. Metab. 83, 3480–3486 (1998)
K.K. Winer, C.W. Ko, J.C. Reynolds et al., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88, 4214–4220 (2003)
K.K. Winer, N. Sinaii, J. Reynolds et al., Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680–2688 (2010)
K.K. Winer, B. Zhang, J.A. Shrader et al., Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. (2011) [Epub ahead of print]
M.R. Rubin, J. Sliney Jr., D.J. McMahon et al., Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos. Int. 21, 1927–1934 (2010)
N.E. Cusano, M.R. Rubin, D. McMahon D et al., Treatment of Hypoparathyroidism with PTH(1-84) is safe and effective for up to 4 years. J. Bone Miner. Res. 26(Suppl 1), S34 (2011). http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx. Accessed 11/04/11
Conflict of interest
Dr. Bilezikian is a consultant for Eli Lilly, NPS Pharmaceuticals, Merck, Novartis, Amgen, and receives research support from NPS Pharmaceuticals and Amgen. Dr. Rubin receives research support from NPS Pharmaceuticals. No conflicts of interest reported for the remaining authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cusano, N.E., Rubin, M.R., Sliney, J. et al. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine 41, 410–414 (2012). https://doi.org/10.1007/s12020-012-9618-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9618-y